Description: Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Home Page: www.xiliotx.com
XLO Technical Analysis
828 Winter Street
Waltham,
MA
02451
United States
Phone:
617 430 4680
Officers
| Name | Title |
|---|---|
| Dr. Rene Russo BCPS, Pharm.D, Pharm.D. | CEO & Director |
| Dr. Martin H. Huber M.D. | Pres and Head of R&D |
| Dr. Uli Bialucha Ph.D. | Chief Scientific Officer |
| Mr. Christopher Frankenfield | Chief Legal & Admin. Officer |
| Julissa Viana | VP of Corp. Communications |
| Mr. Bill Avery Ph.D. | Sr. VP of Nonclinical Devel. |
| Ms. Stacey J. Davis | Chief Bus. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5177 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-10-22 |
| Fiscal Year End: | December |
| Full Time Employees: | 74 |